Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico.

MLA

López-Macías, Constantino, et al. “Phase II Study on the Safety and Immunogenicity of Single-Dose Intramuscular or Intranasal Administration of the AVX/COVID-12 ‘Patria’ Recombinant Newcastle Disease Virus Vaccine as a Heterologous Booster against COVID-19 in Mexico.” Vaccine, vol. 43, no. Pt 2, Jan. 2025, p. 126511. EBSCOhost, https://doi.org/10.1016/j.vaccine.2024.126511.

APA

López-Macías, C., Torres, M., Armenta-Copca, B., Wacher, N. H., Castro-Castrezana, L., Colli-Domínguez, A. A., Rivera-Hernández, T., Torres-Flores, A., Damián-Hernández, M., Ramírez-Martínez, L., la Rosa, G. P.-D., Rojas-Martínez, O., Suárez-Martínez, A., Peralta-Sánchez, G., Carranza, C., Juárez, E., Zamudio-Meza, H., Carreto-Binaghi, L. E., Viettri, M., … Lozano-Dubernard, B. (2025). Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 “Patria” recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico. Vaccine, 43(Pt 2), 126511. https://doi.org/10.1016/j.vaccine.2024.126511

Chicago

López-Macías, Constantino, Martha Torres, Brenda Armenta-Copca, Niels H Wacher, Laura Castro-Castrezana, Andrea Alicia Colli-Domínguez, Tania Rivera-Hernández, et al. 2025. “Phase II Study on the Safety and Immunogenicity of Single-Dose Intramuscular or Intranasal Administration of the AVX/COVID-12 ‘Patria’ Recombinant Newcastle Disease Virus Vaccine as a Heterologous Booster against COVID-19 in Mexico.” Vaccine 43 (Pt 2): 126511. doi:10.1016/j.vaccine.2024.126511.